Ulixertinib (Standard)

• Description:

  Ulixertinib (Standard) is the analytical standard of Ulixertinib. This product is intended for research and analytical applications. Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of [1][2].

• UNSPSC:

  12352100

• Target:

  ERK; Reference Standards

• Related Pathways:

  MAPK/ERK Pathway; Others; Stem Cell/Wnt

• Field of Research:

  Cancer

• Smiles:

  O=C(C1=CC(C2=CC(NC(C)C)=NC=C2Cl)=CN1)N[C@@H](C3=CC=CC(Cl)=C3)CO

• Molecular Formula:

  C21H22Cl2N4O2

• Molecular Weight:

  433.33

• References & Citations:

  [1]Ward RA, et al. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem. 2015 Jun 11;58 (11) :4790-801.|[2]Kumar R, et al. Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2016 Jun 5;125:140-4.|[3]Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4;8 (27) :44295-44311.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference Standards

• CAS Number:

  [869886-67-9]